GH Research PLC (GHRS) stock
GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.53−1.03 (-5.55%)
Close on Nov 20, 2026Market cap $1.09BP/E –Yield –
GH Research free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
GH Research's free cash flow for the twelve months ending Jun 30, 2026 was -$51.84M. For fiscal 2025 it was -$43.67M. The highest annual figure on record is -$289.00K in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$43.67M | – |
| FY2024 | Dec 31, 2024 | -$42.33M | – |
| FY2023 | Dec 31, 2023 | -$33.44M | – |
| FY2022 | Dec 31, 2022 | -$26.27M | – |
| FY2021 | Dec 31, 2021 | -$15.39M | – |
| FY2020 | Dec 31, 2020 | -$330.00K | – |
| FY2019 | Dec 31, 2019 | -$289.00K | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$12.35M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.72M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.94M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.61M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.07M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.06M | – |
See a number that looks wrong?